Nectar Lifescience
NECLIFE NSE
Nectar Lifescience
HealthcareNSE: NECLIFE BSE: 532649 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹232 Cr
Volatility
Moderate
P/E Ratio
-0.9
EBITDA
₹-51.40 Cr
Return on Equity
-9.85%
Debt to Equity
0
Book Value
₹29.97
52W High
₹22.4
52W Low
₹9.3
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.38 times its book value
Weaknesses
4- Company has low interest coverage ratio.
- Company has a low return on equity of -12.3% over last 3 years.
- Contingent liabilities of Rs.269 Cr.
- Promoter holding has decreased over last 3 years: -3.96%
Growth Rate
Revenue Growth
-99.44% lower than
3Y
Net Income Growth
-49.6%
Cash Flow Change
-306% lower than
3Y
ROE
-17.16% lower than
3Y
ROCE
2.48% higher than
3Y
EBITDA Margin (Avg.)
—
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 394 | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 359 | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating Profit | 36 | 27 | 42 | 48 | 40 | -1 | 0 | 0 | -1 | 1 | -2 | -57 | -27 |
| OPM % | 9% | 7% | 9% | 11% | 11% | -10% | -500% | -500% | -16% | 77% | — | -4437% | -6198% |
| Other Income | 0 | 11 | 0 | 1 | 1 | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 18 | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| PBT | 3 | 2 | 2 | 11 | 5 | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax % | 41% | 38% | 36% | 95% | 40% | -2% | 2% | 0% | -1% | 0% | -339% | -22% | -37% |
| Net Profit | 2 | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS in Rs | 0.08 | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.8 | -2.82 | -7.85 | 0.64 | -3.5 | -0.79 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Expenses | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 1,694 | 8 | 88 |
| Operating Profit | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -30 | -8 | -86 |
| OPM % | 16% | 14% | 14% | 13% | 10% | 9% | 7% | 10% | 3.5% | 9% | -1.8% | -2920% | -3520% |
| Other Income | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | 5 | -279 | -162 |
| Interest | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 75 | 36 | 36 |
| Depreciation | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 62 | 0 | 0 |
| PBT | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 | -323 | -285 |
| Tax % | 22% | 15% | 18% | 17% | 19% | 15% | -14% | 26% | -43% | 73% | -30% | -9% | — |
| Net Profit | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS in Rs | 2.95 | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 | -11.5 |
| Div. Payout % | 3% | 4% | 2% | 2% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
| Reserves | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 |
| Borrowings | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 0 |
| Other Liabilities | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 39 |
| Total Liabilities | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
| Fixed Assets | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 |
| CWIP | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 |
| Other Assets | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 504 |
| Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | 169 | -349 |
| Investing | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Financing | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -767 |
| Net Cash Flow | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | 0 | 2 | -1 | 93 |
| Free Cash Flow | 64 | 87 | 174 | 32 | 204 | 249 | -10 | 110 | 183 | 195 | 126 | -341 |
| CFO/OP | 56 | 74 | 92 | 33 | 96 | 134 | 23 | 60 | 252 | 148 | -574 | 4,132 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 107 | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 | 76 | — |
| Inventory Days | 253 | 260 | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 | 184 | — |
| Days Payable | 146 | 154 | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 | 117 | — |
| Cash Conversion Cycle | 207 | 213 | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 | 143 | — |
| Working Capital Days | 40 | 41 | 45 | 67 | 46 | 53 | 6 | 73 | 77 | 63 | 43 | — |
| ROCE % | 11% | 10% | 10% | 9% | 10% | 8% | 3% | 5% | 0% | 6% | -5% | 0% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Nectar Lifescience insights
68 extracted metrics + investor summaries across FY10–FY26.
Documents
1
Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (LODR) Regulations, 2015
28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded. 28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded.
2
Update On Slump Sale
28 Apr - Capnest slump sale completion extended to on or before July 31, 2026. 28 Apr - Capnest slump sale completion extended to on or before July 31, 2026.
3
Disclosure As Per Regulation 30 Of The Securities And Exchange Of Board Of India (LODR) Regulations, 2015
28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded. 28 Apr - Income tax objections for AY 2017-18 decided in company’s favor; matter fully concluded.
4
Update On Slump Sale
28 Apr - Capnest slump sale completion extended to on or before July 31, 2026. 28 Apr - Capnest slump sale completion extended to on or before July 31, 2026.
5
Compliances-Reg.24(A)-Annual Secretarial Compliance
18 Apr - Secretarial compliance report for FY2026 notes minor delays in results/meeting notices and two fines. 18 Apr - Secretarial compliance report for FY2026 notes minor delays in results/meeting notices and two fines.
Frequently Asked Questions about Nectar Lifescience
What does Nectar Lifescience Ltd do?
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]
Where is Nectar Lifescience Ltd (NECLIFE) listed?
Nectar Lifescience Ltd trades as NECLIFE on the NSE and under code 532649 on the BSE.
Which sector does Nectar Lifescience Ltd belong to?
Nectar Lifescience Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Nectar Lifescience Ltd?
Nectar Lifescience Ltd has a market capitalisation of ₹231.95 Cr, which places it in the Small Cap band.
What is the PE ratio of Nectar Lifescience Ltd?
Nectar Lifescience Ltd trades at a PE ratio of -0.90, against a book value of ₹29.97 per share.
What is the 52-week high and low of Nectar Lifescience Ltd?
Over the last 52 weeks Nectar Lifescience Ltd has traded between ₹9.3 and ₹22.4.
What is the Return on Equity (ROE) of Nectar Lifescience Ltd?
Nectar Lifescience Ltd reported a return on equity of -9.85%. Its debt-to-equity ratio is 0.00.
Company Information
Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations[1]
Website neclife.com
CEO Mr. Sanjiv Goyal
Employees 1,786
Listed 2005-07-18
Face Value ₹ 1
Issued Size 22,42,60,970
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NECLIFE.md for Nectar Lifescience Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.